Gene Therapy Working Group

The Gene Therapy Working Group is a permanent working group of the SECB. It supports the SECB in its advisory tasks concerning the authorization of clinical trials of gene therapy or with genetically modified organisms (GMOs) as well as market authorizations of such products.

Members of the Gene Therapy Working Group (external experts)

Chair

  • Pedro Romero, Prof. em. MD, Deputy scientific managing director Ludwig Institute for Cancer Research, Lausanne

Deputy

  • Pascal Meylan, Prof. em. MD, University Hospital Center (CHUV), Lausanne

Members

  • Fabio Candotti, Prof. MD, Service d’immunologie et allergie, CHUV Lausanne
  • Carlo V. Catapano, Dr. med. et phil. nat., Oncology Institute of Southern Switzerland, Bellinzona
  • Angela Ciuffi, Prof. PhD, Lausanne University Hospital Center and University of Lausanne (CHUV-UNIL)
  • Ben Hale, Prof. PhD, Institut für Medizinische Virologie, Universität Zürich
  • Hussein Y. Naim, Prof. PhD, Former Director of Vaccines Research and Development, Berna Biotech-Crucell, Switzerland; Life Sciences and Vaccines Consultant
  • Steve Pascolo, PD Dr., Departement für Dermatologie, Universität Zürich
  • Patrick Roth, Prof. MD, Universitätsspital Zürich
  • Sandro Rusconi, Prof. em. Dr. phil. nat., Repubblica e Cantone Ticino, Divisione della Cultura e degli Studi Universitari, Bellinzona
  • Bernard Schneider, MER, PhD, Plateforme technologique Bertarelli de thérapie génique, EPFL
  • Silke Stertz, Prof. Dr., Institut für Medizinische Virologie, Universität Zürich

Executive Office

  • Elisabetta Peduzzi, PhD, Executive Manager SECB, Bern

To the top

Last edition: 02.12.2022